top of page
  • Jonathan Poyer

AstraZeneca Acquires 2 Pharma Companies for over $2.1B Combined - Index Still Down for March

Updated: Apr 11

The S&P Biotechnology Select Index finished the week of March 15th up 6.02% for the year. Since then, we have seen a slight down move as the sector responds to rate moves from the Fed and momentum trading across the board.

Hotter than expected inflation data has tempered expectations for near term rate cuts. Additional clues into the direction for monetary policy may come at Fed’s upcoming policy meeting (March 19-20). In the broader market, the weight of high momentum stocks in US equity markets reached all time high. The momentum factor has led so far in 2024, lifting the S&P to a 17th record high for the year. M&A has been quiet in recent weeks on the biotech front, but favorable regulatory activity continues to showcase innovative new medicines that are advancing forward.

Week Ending March 15th, 2024:

  • Biotech: 7 Transactions (1 Follow-On, 5 PIPEs, and 1 RD) totaling just over $700M

  • Med Tech: No Current Week Transactions

2024 YTD:

  • 90 Biotech transactions totaling just under $17B v. 2023 YTD: 34 Biotech transactions totaling just under $4B

  • 3 Med Tech transactions totaling just over $200M v. 2023 YTD: 6 Med Tech transactions totaling just over $400M

Private Transactions:

  • Biotech: 50 US Transactions / 20 European Transactions

  • Med Tech: 27 US Transactions / 11 European Transactions

Recent Transactions:

AbbVie acquired Landos Biopharma for $138M or $20.42/share

AstraZeneca acquired Fusion Pharmaceuticals for $2B or $21/share

AstraZeneca acquired Amolyt Pharma for $800M

12 views0 comments


bottom of page